Please use this identifier to cite or link to this item:
|Title:||Multicenter, Randomized Clinical Trial to Assess the Effectiveness of Intravitreal Injections of Bevacizumab, Triamcinolone, or Their Combination in the Treatment of Diabetic Macular Edema|
|Authors:||Neto, Hermelino O. [UNIFESP]|
Regatieri, Caio V. [UNIFESP]
Nobrega, Mario J.
Muccioli, Cristina [UNIFESP]
Casella, Antonio M.
Andrade, Rafael E.
Maia, Mauricio [UNIFESP]
Kniggendorf, Vinicius [UNIFESP]
Branco, Andre C.
Belfort, Rubens, Jr. [UNIFESP]
|Citation:||Ophthalmic Surgery Lasers & Imaging Retina. Thorofare, v. 48, n. 9, p. 734-740, 2017.|
|Abstract:||BACKGROUND AND OBJECTIVE: To evaluate the efficacy of combined bevacizumab-triamcinolone intravitreal injection in the treatment of diabetic macular edema (DME) compared to monotherapy. PATIENTS AND METHODS: At eight clinical sites, 111 patients with DME were randomly assigned to receive an intravitreal injection of bevacizumab (Avastin|
Genentech, South San Francisco, CA), triamcinolone (Ophthalmos Pharmaceutical Industry, Sao Paulo-SP, Brazil), or their combination. The primary outcome was visual acuity (VA) at 6 months' follow-up. RESULTS: The average number of injections was 3.2 in the bevacizumab group, 2.4 in the combined group, and 2.1 in the triamcinolone group. All groups presented with improvements in VA (P < .001)
however, no differences between groups were observed (P =.436). Mean reduction in central retinal thickness was statistically different only between the triamcinolone and bevacizumab groups (P < .015). CONCLUSION: Mono-or combination therapy was effective for DME treatment. No synergistic effects were observed
however, triamcinolone alone or a drug combination may reduce the number of injections required when compared to bevacizumab alone.
|Appears in Collections:||Artigo|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.